A growing body of evidence suggests that there is a discrepancy in FMNL2 expression in multiple cancers, for instance, upregulated in colorectal cancer [10], melanoma [7], and gastric cancer [11], but downregulated in hepatocellular carcinoma [12]. This evidence concerns the gene FMNL2 and colorectal cancer.